The purpose of this study is to evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP for the treatment of the GCB subtype of DLBCL.
Thank you for your interest, but this study will start enrolling soon.
International (Germany, Ireland, Italy, United Kingdom)
Natalie Grover
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
25-0288
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
